Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)

Stock Information for Rezolute Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Rezolute Inc.

Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting
Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update
Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer
Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism
Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema ("DME")
Stonegate Healthcare Partners Announces Black Friday Biotech Special Report For an "XBI-MAS"
Rezolute to Participate in BTIG's 3rd Annual Ophthalmology Day

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.